Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "Antoni Ribas" Clear advanced filters

  • Tumour cells can respond to targeted immune-cell therapies by losing proteins that mark them as being cancerous. Subverting this resistance mechanism may lead to more durable cancer-treatment strategies. See Letter p.412

    • Antoni Ribas
    • Paul C. Tumeh
    News & Views
    Nature
    Volume: 490, P: 347-348

  • Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target. The authors describe the scientific basis for the targeting ofBRAFmutations in cancer, the early clinical data with BRAF inhibitors, and how combinatorial therapies may address the current limitations of their use in the clinic.

    • Antoni Ribas
    • Keith T. Flaherty
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 8, P: 426-433

  • In less than a decade, the treatment landscape of metastatic melanoma has changed dramatically. Novel targeted agents and immunotherapies are revolutionizing patient outcomes, but the range of available drugs complicates clinical decision-making. Herein, the authors chart the therapeutic advances and review the current evidence that can be used to guide therapeutic decisions for individual patients with metastatic melanoma, highlighting knowledge gaps.

    • Jason J. Luke
    • Keith T. Flaherty
    • Georgina V. Long
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 14, P: 463-482

  • Single-cell analysis tools are rapidly evolving, enabling cellular analyses at the genomic, transcriptomic and proteomic levels. Here, Heath and colleagues provide an overview of recently developed single-cell analysis technologies, discuss their biological applications and highlight their potential uses in drug discovery and development, focusing on the field of oncology.

    • James R. Heath
    • Antoni Ribas
    • Paul S. Mischel
    Reviews
    Nature Reviews Drug Discovery
    Volume: 15, P: 204-216

  • Tumour cells can evade the immune response through different strategies, with the tumour microenvironment being a key determinant of which pathways become activated to restrain antitumour immunity. The authors of this Review describe the four major types of therapeutic interventions required in combinations to generate a strong antitumour response. Importantly, they also discuss which combination therapies might effectively engage immunity to suppress tumour progression in four different scenarios defined by the composition of the immune tumour microenvironment.

    • Mark J. Smyth
    • Shin Foong Ngiow
    • Michele W. L. Teng
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 13, P: 143-158